US Patent 11332438 Creatine prodrugs, compositions and methods of use thereof
Patent 11332438 was granted and assigned to Ultragenyx Pharmaceutical on May, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113324380
Date of Patent
May 17, 2022
0Patent Application Number
167649690
Date Filed
December 3, 2018
0Patent Citations
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113324380
Date of Patent
May 17, 2022
0Patent Application Number
167649690
Date Filed
December 3, 2018
0Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+130 characters)
US Patent 11332438 Creatine prodrugs, compositions and methods of use thereof
Article
The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11332438
Date of patent
May 17, 2022
Patent application number
16764969
Date Filed
December 3, 2018
Patent citations
Patent primary examiner
Find more entities like US Patent 11332438 Creatine prodrugs, compositions and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
